EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Regorafenib as a potential drug for severe COVID ‐19: inhibition of inflammasome activation in mice

Ju Hwan Jeong, Sun-Ok Kim, Seong Cheol Min, Eung-Gook Kim, Min-Suk Song, Eun-Young Shin iD

FEBS Open Bio · 2025

DOI: 10.1002/2211-5463.70002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift FEBS Open Bio, 2025. Verfasst von Ju Hwan Jeong und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Chungbuk National University College of Medicine and Medical Research Center, Chungbuk National University Hospital, Cheo…. Hauptthemen laut MEDLINE: Phenylurea Compounds, Pyridines, COVID-19 Drug Treatment, Inflammasomes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Chungbuk National University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

SARS‐CoV‐2 infection can lead to severe COVID‐19, particularly in elderly individuals and those with compromised immunity. Cellular senescence has been implicated as a key pathogenic mechanism. This study investigated the therapeutic potential of regorafenib, a previously characterized senomorphic drug, for severe COVID‐19. SARS‐CoV‐2 virus‐infected K18‐hACE2 mice, overexpressing the human ACE2 receptor, exhibited 100% mortality by 10 days post infection. Regorafenib treatment significantly improved survival rates, approximately 43% remaining alive. Mechanistically, regorafenib effectively suppressed type I and II interferon and cytokine signaling. Notably, regorafenib inhibited NLR family pyrin domain containing 3 (NLRP3) inflammasome activation, a key driver of the cytokine storm associated with severe COVID‐19. Our findings elucidate the molecular mechanisms underlying therapeutic effects of regorafenib and suggest its potential use as a promising treatment option for severe COVID‐19.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phenylurea CompoundsPyridinesCOVID-19 Drug TreatmentInflammasomesAnimalsMiceSARS-CoV-2HumansCOVID-19NLR Family, Pyrin Domain-Containing 3 ProteinAngiotensin-Converting Enzyme 2Disease Models, AnimalMice, TransgenicCytokine Release Syndrome

Stichwörter der Autor:innen

K18‐hACE2SARS‐CoV‐2infectioninflammasomeregorafenib

Substanzen

Phenylurea CompoundsPyridinesregorafenibInflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinAngiotensin-Converting Enzyme 2ACE2 protein, human

Autor:innen und Institutionen

  • Department of Microbiology, Chungbuk National University College of Medicine and Medical Research Center, Chungbuk National University Hospital, Cheongju, Republic of Korea.
  • Department of Biochemistry, Chungbuk National University College of Medicine and Medical Research Center, Chungbuk National University Hospital, Cheongju, Republic of Korea.

ORCID-Profile: Eun-Young Shin

Förderung

  • National Research Foundation of Korea
  • Chungbuk National University

Zitieren

APA

Jeong, J. H., Kim, S. O., Min, S. C., Kim, E. G., Song, M. S., & Shin, E. Y. (2025). Regorafenib as a potential drug for severe COVID ‐19: inhibition of inflammasome activation in mice. FEBS Open Bio. https://doi.org/10.1002/2211-5463.70002

Vancouver

Jeong JH, Kim SO, Min SC, Kim EG, Song MS, Shin EY. Regorafenib as a potential drug for severe COVID ‐19: inhibition of inflammasome activation in mice. FEBS Open Bio. 2025. doi:10.1002/2211-5463.70002

BibTeX
@article{Jeong2025,
  author = {Jeong, Ju Hwan and Kim, Sun-Ok and Min, Seong Cheol and Kim, Eung-Gook and Song, Min-Suk and Shin, Eun-Young},
  title = {Regorafenib as a potential drug for severe COVID ‐19: inhibition of inflammasome activation in mice},
  journal = {FEBS Open Bio},
  year = {2025},
  doi = {10.1002/2211-5463.70002}
}
Kostenlos starten →